Mortalidad por infarto del miocardio en Chile: Trombolíticos o angioplastía

• Fernando Florenzano U ^[1]
  1. [1] Universidad de Chile/Clínica Las Condes Facultad de Medicina Departamento de Medicina Oriente
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 139, Nº. 11, 2011, págs. 1393-1395
• Idioma: español
• Títulos paralelos:
  • Acute myocardial infarction mortality in Chile: Thrombolysis or angioplasty
• Enlaces
  • Texto completo
• Resumen

  • During recent decades, acute myocardial infarction short-term mortality has decreased to one digit levels, in the United States. Data from Chilean registries give figures around 11% for patients receiving thrombolysis, and 5 to 6 % for patients treated with angioplasty. The decrease in mortality in Chile is related to the implementation of the AUGE program at a national level, initiative than gives patients the opportunity to receive at least thrombolytic therapy as well as a standardized and rapid diagnosis and treatment for this condition. There is a lack of Outcome Research studies in Chile, that would guide public health decisions such as the use of fibrin-specific agents for early presentation and high risk cases, and a rational system providing better access to primary angioplasty.